First Republic Investment Management Inc. grew its holdings in Becton Dickinson and Co (NYSE:BDX) by 1.1% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 111,021 shares of the medical instruments supplier’s stock after acquiring an additional 1,254 shares during the quarter. First Republic Investment Management Inc.’s holdings in Becton Dickinson and were worth $23,765,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Koch Industries Inc. boosted its position in shares of Becton Dickinson and by 45,268.7% in the 2nd quarter. Koch Industries Inc. now owns 1,398,264 shares of the medical instruments supplier’s stock valued at $1,391,000 after purchasing an additional 1,395,182 shares during the period. BlackRock Inc. boosted its position in shares of Becton Dickinson and by 6.0% in the 4th quarter. BlackRock Inc. now owns 18,811,302 shares of the medical instruments supplier’s stock valued at $4,026,750,000 after purchasing an additional 1,071,288 shares during the period. Atlantic Trust Group LLC boosted its position in shares of Becton Dickinson and by 597.3% in the 3rd quarter. Atlantic Trust Group LLC now owns 451,035 shares of the medical instruments supplier’s stock valued at $88,381,000 after purchasing an additional 386,349 shares during the period. DSM Capital Partners LLC acquired a new stake in shares of Becton Dickinson and in the 3rd quarter valued at about $75,155,000. Finally, Alpine Associates Management Inc. acquired a new stake in shares of Becton Dickinson and in the 4th quarter valued at about $55,594,000. Institutional investors and hedge funds own 77.50% of the company’s stock.
Shares of Becton Dickinson and Co (NYSE BDX) opened at $218.32 on Friday. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. The firm has a market capitalization of $58,227.23, a P/E ratio of 22.69, a price-to-earnings-growth ratio of 1.56 and a beta of 1.12. Becton Dickinson and Co has a 1 year low of $175.66 and a 1 year high of $248.39.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the consensus estimate of $2.41 by $0.07. The business had revenue of $3.08 billion during the quarter, compared to analysts’ expectations of $3.05 billion. Becton Dickinson and had a return on equity of 16.19% and a net margin of 2.71%. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm earned $2.33 EPS. equities analysts predict that Becton Dickinson and Co will post 10.94 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, March 30th. Stockholders of record on Friday, March 9th will be issued a $0.75 dividend. The ex-dividend date is Thursday, March 8th. This represents a $3.00 annualized dividend and a dividend yield of 1.37%. Becton Dickinson and’s dividend payout ratio is currently 229.01%.
A number of brokerages recently issued reports on BDX. Zacks Investment Research raised Becton Dickinson and from a “hold” rating to a “buy” rating and set a $234.00 target price for the company in a research report on Tuesday, October 31st. Morgan Stanley increased their price objective on Becton Dickinson and from $245.00 to $250.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 7th. Bank of America reaffirmed a “buy” rating and set a $260.00 price objective on shares of Becton Dickinson and in a research report on Friday, January 19th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $260.00 price objective (up from $223.00) on shares of Becton Dickinson and in a research report on Tuesday, February 6th. Finally, Evercore ISI started coverage on Becton Dickinson and in a research report on Wednesday, January 3rd. They set an “outperform” rating and a $245.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $237.27.
In other news, Director Timothy M. Ring sold 269,661 shares of the firm’s stock in a transaction that occurred on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total value of $58,737,559.02. Following the completion of the sale, the director now directly owns 295,753 shares of the company’s stock, valued at approximately $64,420,918.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.00% of the stock is owned by company insiders.
WARNING: This article was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/23/becton-dickinson-and-co-bdx-stake-lifted-by-first-republic-investment-management-inc.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.